Difference between revisions of "Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
| Line 4: | Line 4: | ||
|- | |- | ||
!'''Disease'''!!'''Page Type'''!!'''Author''' | !'''Disease'''!!'''Page Type'''!!'''Author''' | ||
| − | !'''Date Assigned (Target | + | !'''Date Assigned to Author (Target Completion Date)'''!!'''Associate Editor''' |
| − | !Author Content Pending or Complete (Date Completed) | + | !'''Author Content Pending or Complete (Date Completed)''' |
| − | !Editor Reviewed (Date) | + | !'''Date Completed by Author''' |
| − | !Notes | + | !'''Editor Reviewed (Date of Last Review)''' |
| + | !'''Notes''' | ||
|- | |- | ||
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera | ||
| Line 13: | Line 14: | ||
|Fabiola Quintero-Rivera (FQR) | |Fabiola Quintero-Rivera (FQR) | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 21: | Line 23: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 29: | Line 32: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 37: | Line 41: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 45: | Line 50: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 53: | Line 59: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 61: | Line 68: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 69: | Line 77: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 74: | Line 83: | ||
|'''''Mastocytosis'''''||'''''Overview'''''|| | |'''''Mastocytosis'''''||'''''Overview'''''|| | ||
| ||FQR | | ||FQR | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 83: | Line 93: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 91: | Line 102: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 99: | Line 111: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 106: | Line 119: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 113: | Line 127: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 120: | Line 135: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 127: | Line 143: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 134: | Line 151: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 143: | Line 161: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|NON-WHO ENTITY | |NON-WHO ENTITY | ||
| Line 152: | Line 171: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|NON-WHO ENTITY | |NON-WHO ENTITY | ||
| Line 159: | Line 179: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 166: | Line 187: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 173: | Line 195: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 180: | Line 203: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 187: | Line 211: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 194: | Line 219: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 200: | Line 226: | ||
| | | | ||
|FQR | |FQR | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 208: | Line 235: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 215: | Line 243: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 222: | Line 251: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 229: | Line 259: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 236: | Line 267: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 243: | Line 275: | ||
|FQR | |FQR | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 250: | Line 283: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 257: | Line 291: | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 262: | Line 297: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 270: | Line 306: | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 276: | Line 313: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 282: | Line 320: | ||
| ||JH / MS | | ||JH / MS | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 288: | Line 327: | ||
| ||JH / MS | | ||JH / MS | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 294: | Line 334: | ||
| ||JH / MS | | ||JH / MS | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 300: | Line 341: | ||
| ||JH / MS | | ||JH / MS | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 306: | Line 348: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 312: | Line 355: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 319: | Line 363: | ||
|JH / MS | |JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 325: | Line 370: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 331: | Line 377: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 337: | Line 384: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 343: | Line 391: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 349: | Line 398: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 355: | Line 405: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Need permission for figure? Update WHO? | |Need permission for figure? Update WHO? | ||
| Line 361: | Line 412: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 367: | Line 419: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 373: | Line 426: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Add WHO reference | |Add WHO reference | ||
| Line 379: | Line 433: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 385: | Line 440: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 391: | Line 447: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 397: | Line 454: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Check reference format | |Check reference format | ||
| Line 403: | Line 461: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 409: | Line 468: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 415: | Line 475: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 421: | Line 482: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 427: | Line 489: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 433: | Line 496: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 439: | Line 503: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 445: | Line 510: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 451: | Line 517: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 457: | Line 524: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 463: | Line 531: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 469: | Line 538: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Need permission for figure? | |Need permission for figure? | ||
| Line 475: | Line 545: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 481: | Line 552: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 487: | Line 559: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 493: | Line 566: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 499: | Line 573: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Check reference format | |Check reference format | ||
| Line 505: | Line 580: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 511: | Line 587: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 517: | Line 594: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Check reference format | |Check reference format | ||
| Line 523: | Line 601: | ||
| ||JH / MS | | ||JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 529: | Line 608: | ||
| ||JH / MS | | ||JH / MS | ||
|?? | |?? | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 535: | Line 615: | ||
| ||JH / MS | | ||JH / MS | ||
|?? | |?? | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 544: | Line 625: | ||
|JH / MS | |JH / MS | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|NON-WHO ENTITY | |NON-WHO ENTITY | ||
| Line 553: | Line 635: | ||
|JH / MS | |JH / MS | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
|NON-WHO ENTITY | |NON-WHO ENTITY | ||
| Line 562: | Line 645: | ||
|JH / MS | |JH / MS | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
|NON-WHO ENTITY | |NON-WHO ENTITY | ||
| Line 567: | Line 651: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 573: | Line 658: | ||
|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| | |'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| | ||
| ||Yassmine Akkari (YA) | | ||Yassmine Akkari (YA) | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 579: | Line 665: | ||
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| | |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 585: | Line 672: | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease|| | | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 593: | Line 681: | ||
|YA | |YA | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 598: | Line 687: | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| | | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 604: | Line 694: | ||
| B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| | | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 614: | Line 705: | ||
|YA | |YA | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 619: | Line 711: | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| | | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 625: | Line 718: | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| | | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 633: | Line 727: | ||
|YA | |YA | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 638: | Line 733: | ||
| B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| | | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 644: | Line 740: | ||
| B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 650: | Line 747: | ||
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 656: | Line 754: | ||
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 662: | Line 761: | ||
|NK-Lymphoblastic Leukemia/Lymphoma||Disease|| | |NK-Lymphoblastic Leukemia/Lymphoma||Disease|| | ||
| ||YA | | ||YA | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 672: | Line 772: | ||
|YA | |YA | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
|NON-WHO ENTITY | |NON-WHO ENTITY | ||
| Line 677: | Line 778: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 683: | Line 785: | ||
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| | |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| | ||
| ||Snehal Patel (SP) | | ||Snehal Patel (SP) | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 691: | Line 794: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 698: | Line 802: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 705: | Line 810: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 712: | Line 818: | ||
|SP | |SP | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Malini to review | |Malini to review | ||
| Line 719: | Line 826: | ||
|SP | |SP | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Malini to review | |Malini to review | ||
| Line 726: | Line 834: | ||
|SP | |SP | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Malini to review | |Malini to review | ||
| Line 733: | Line 842: | ||
|SP | |SP | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Malini to review | |Malini to review | ||
| Line 740: | Line 850: | ||
|SP | |SP | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
|Malini to review | |Malini to review | ||
| Line 747: | Line 858: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 754: | Line 866: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 759: | Line 872: | ||
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 765: | Line 879: | ||
|'''''Heavy Chain Diseases'''''||'''''Overview'''''|| | |'''''Heavy Chain Diseases'''''||'''''Overview'''''|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 771: | Line 886: | ||
| Mu Heavy Chain Disease||Disease|| | | Mu Heavy Chain Disease||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 777: | Line 893: | ||
| Gamma Heavy Chain Disease||Disease|| | | Gamma Heavy Chain Disease||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 783: | Line 900: | ||
| Alpha Heavy Chain Disease||Disease|| | | Alpha Heavy Chain Disease||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 791: | Line 909: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 798: | Line 917: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 805: | Line 925: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 812: | Line 933: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 819: | Line 941: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 824: | Line 947: | ||
|''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 830: | Line 954: | ||
| Primary Amyloidosis||Disease|| | | Primary Amyloidosis||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 836: | Line 961: | ||
| Light Chain and Heavy Chain Deposition Disease||Disease|| | | Light Chain and Heavy Chain Deposition Disease||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 842: | Line 968: | ||
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 848: | Line 975: | ||
| POEMS Syndrome||Disease|| | | POEMS Syndrome||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 854: | Line 982: | ||
| TEMPI Syndrome||Disease|| | | TEMPI Syndrome||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 862: | Line 991: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 867: | Line 997: | ||
|Nodal Marginal Zone Lymphoma||Disease|| | |Nodal Marginal Zone Lymphoma||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 875: | Line 1,006: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 882: | Line 1,014: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 889: | Line 1,022: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 896: | Line 1,030: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 903: | Line 1,038: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 910: | Line 1,046: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 915: | Line 1,052: | ||
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 921: | Line 1,059: | ||
|Primary Cutaneous Follicle Centre Lymphoma||Disease|| | |Primary Cutaneous Follicle Centre Lymphoma||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 929: | Line 1,068: | ||
|SP | |SP | ||
|PENDING - due 8/15/20 | |PENDING - due 8/15/20 | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 936: | Line 1,076: | ||
|SP | |SP | ||
|PENDING - due 8/31/20 | |PENDING - due 8/31/20 | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 943: | Line 1,084: | ||
|SP | |SP | ||
|PENDING - due 8/15/20 | |PENDING - due 8/15/20 | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 948: | Line 1,090: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 956: | Line 1,099: | ||
|Greg Corboy (GC) | |Greg Corboy (GC) | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 961: | Line 1,105: | ||
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 967: | Line 1,112: | ||
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| | |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 973: | Line 1,119: | ||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| | |Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 979: | Line 1,126: | ||
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | |EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 985: | Line 1,133: | ||
|EBV-Positive Mucocutaneous Ulcer||Disease|| | |EBV-Positive Mucocutaneous Ulcer||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 991: | Line 1,140: | ||
|Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease|| | |Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 997: | Line 1,147: | ||
| Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease|| | | Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,003: | Line 1,154: | ||
|Lymphomatoid Granulomatosis||Disease|| | |Lymphomatoid Granulomatosis||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,009: | Line 1,161: | ||
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease|| | |Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,015: | Line 1,168: | ||
|Intravascular Large B-cell Lymphoma||Disease|| | |Intravascular Large B-cell Lymphoma||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,021: | Line 1,175: | ||
|ALK-Positive Large B-cell Lymphoma||Disease|| | |ALK-Positive Large B-cell Lymphoma||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,028: | Line 1,183: | ||
| ||GC | | ||GC | ||
|Complete | |Complete | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,033: | Line 1,189: | ||
|Primary Effusion Lymphoma||Disease|| | |Primary Effusion Lymphoma||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,039: | Line 1,196: | ||
|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| | |'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,045: | Line 1,203: | ||
| Multicentric Castleman Disease||Disease|| | | Multicentric Castleman Disease||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,051: | Line 1,210: | ||
| HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | | HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,057: | Line 1,217: | ||
| HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease|| | | HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,063: | Line 1,224: | ||
|Burkitt Lymphoma||Disease|| | |Burkitt Lymphoma||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,069: | Line 1,231: | ||
|Burkitt-Like Lymphoma with 11q Aberration||Disease|| | |Burkitt-Like Lymphoma with 11q Aberration||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,075: | Line 1,238: | ||
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| | |'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,081: | Line 1,245: | ||
| High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| | | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,087: | Line 1,252: | ||
| High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,093: | Line 1,259: | ||
|B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| | |B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| | ||
| ||GC | | ||GC | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,099: | Line 1,266: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,105: | Line 1,273: | ||
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''|| | |'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''|| | ||
| ||Snehal Patel (SP) | | ||Snehal Patel (SP) | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,112: | Line 1,281: | ||
| ||SP | | ||SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,118: | Line 1,288: | ||
| ||SP | | ||SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,124: | Line 1,295: | ||
| ||SP | | ||SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,129: | Line 1,301: | ||
|Aggressive NK-cell Leukemia||Disease|| | |Aggressive NK-cell Leukemia||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,135: | Line 1,308: | ||
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| | |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,141: | Line 1,315: | ||
| Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease|| | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,147: | Line 1,322: | ||
| Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| | | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,153: | Line 1,329: | ||
| Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,159: | Line 1,336: | ||
| Severe Mosquito Bite Allergy||Disease|| | | Severe Mosquito Bite Allergy||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,165: | Line 1,343: | ||
|Adult T-cell Leukemia/Lymphoma||Disease|| | |Adult T-cell Leukemia/Lymphoma||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,171: | Line 1,350: | ||
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| | |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,179: | Line 1,359: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,186: | Line 1,367: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,193: | Line 1,375: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,200: | Line 1,383: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,207: | Line 1,391: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,213: | Line 1,398: | ||
| ||SP | | ||SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,218: | Line 1,404: | ||
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| | |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,224: | Line 1,411: | ||
|Mycosis Fungoides||Disease|| | |Mycosis Fungoides||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,230: | Line 1,418: | ||
|Sézary Syndrome||Disease|| | |Sézary Syndrome||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,236: | Line 1,425: | ||
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''|| | |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,242: | Line 1,432: | ||
| Lymphomatoid Papulosis||Disease|| | | Lymphomatoid Papulosis||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,248: | Line 1,439: | ||
| Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease|| | | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,254: | Line 1,446: | ||
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''|| | |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,260: | Line 1,453: | ||
| Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease|| | | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,266: | Line 1,460: | ||
| Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease|| | | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,272: | Line 1,467: | ||
| Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease|| | | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,278: | Line 1,474: | ||
| Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease|| | | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,284: | Line 1,481: | ||
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,290: | Line 1,488: | ||
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| | |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,298: | Line 1,497: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,305: | Line 1,505: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,310: | Line 1,511: | ||
| Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease|| | | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease|| | ||
| ||SP | | ||SP | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,318: | Line 1,520: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,325: | Line 1,528: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,332: | Line 1,536: | ||
|SP | |SP | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,337: | Line 1,542: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,343: | Line 1,549: | ||
|'''''Hodgkin Lymphomas'''''||'''''Overview'''''|| | |'''''Hodgkin Lymphomas'''''||'''''Overview'''''|| | ||
| ||Associate Editor?? | | ||Associate Editor?? | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,349: | Line 1,556: | ||
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease|| | |Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,355: | Line 1,563: | ||
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''|| | |'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,361: | Line 1,570: | ||
| Nodular Sclerosis Classic Hodgkin Lymphoma||Disease|| | | Nodular Sclerosis Classic Hodgkin Lymphoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,367: | Line 1,577: | ||
| Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease|| | | Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,373: | Line 1,584: | ||
| Mixed Cellularity Classic Hodgkin Lymphoma||Disease|| | | Mixed Cellularity Classic Hodgkin Lymphoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,379: | Line 1,591: | ||
| Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease|| | | Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,385: | Line 1,598: | ||
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| | |'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,391: | Line 1,605: | ||
|Lymphomas Associated with HIV Infection||Disease|| | |Lymphomas Associated with HIV Infection||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,397: | Line 1,612: | ||
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''|| | |'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,403: | Line 1,619: | ||
| Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease|| | | Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,413: | Line 1,630: | ||
| | | | ||
|PENDING | |PENDING | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,418: | Line 1,636: | ||
|''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''|| | |''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,424: | Line 1,643: | ||
| Monomorphic B-cell PTLD||Disease|| | | Monomorphic B-cell PTLD||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,430: | Line 1,650: | ||
| Monomorphic T/NK-cell PTLD||Disease|| | | Monomorphic T/NK-cell PTLD||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,436: | Line 1,657: | ||
| Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease|| | | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,442: | Line 1,664: | ||
|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease|| | |Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,448: | Line 1,671: | ||
|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''|| | |'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,454: | Line 1,678: | ||
|Histiocytic Sarcoma||Disease|| | |Histiocytic Sarcoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,460: | Line 1,685: | ||
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''|| | |'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,466: | Line 1,692: | ||
| Langerhans Cell Histiocytosis||Disease|| | | Langerhans Cell Histiocytosis||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,472: | Line 1,699: | ||
| Langerhans Cell Sarcoma||Disease|| | | Langerhans Cell Sarcoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,478: | Line 1,706: | ||
|Indeterminate Dendritic Cell Tumour||Disease|| | |Indeterminate Dendritic Cell Tumour||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,484: | Line 1,713: | ||
|Interdigitating Dendritic Cell Sarcoma||Disease|| | |Interdigitating Dendritic Cell Sarcoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,490: | Line 1,720: | ||
|Follicular Dendritic Cell Sarcoma||Disease|| | |Follicular Dendritic Cell Sarcoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,496: | Line 1,727: | ||
| Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| | | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,502: | Line 1,734: | ||
|Fibroblastic Reticular Cell Tumor||Disease|| | |Fibroblastic Reticular Cell Tumor||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,508: | Line 1,741: | ||
|Disseminated Juvenile Xanthogranuloma||Disease|| | |Disseminated Juvenile Xanthogranuloma||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,514: | Line 1,748: | ||
|Erdheim-Chester Disease||Disease|| | |Erdheim-Chester Disease||Disease|| | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,520: | Line 1,755: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,526: | Line 1,762: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,532: | Line 1,769: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,538: | Line 1,776: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,544: | Line 1,783: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,550: | Line 1,790: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,556: | Line 1,797: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,562: | Line 1,804: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,568: | Line 1,811: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,574: | Line 1,818: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,580: | Line 1,825: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,586: | Line 1,832: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,592: | Line 1,839: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,598: | Line 1,846: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,604: | Line 1,853: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,610: | Line 1,860: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,616: | Line 1,867: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,622: | Line 1,874: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,628: | Line 1,881: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
| Line 1,634: | Line 1,888: | ||
| || || | | || || | ||
| || | | || | ||
| + | | | ||
| | | | ||
| | | | ||
Revision as of 13:05, 7 August 2020
| Disease | Page Type | Author | Date Assigned to Author (Target Completion Date) | Associate Editor | Author Content Pending or Complete (Date Completed) | Date Completed by Author | Editor Reviewed (Date of Last Review) | Notes |
|---|---|---|---|---|---|---|---|---|
| Myeloproliferative Neoplasms (MPN) | Overview | Mark Evans (trainee), Fabiola Quintero-Rivera | Fabiola Quintero-Rivera (FQR) | PENDING | ||||
| Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive | Disease | Mark Evans (trainee)+Jack Reid (trainee)+Fabiola Quintero-Rivera | FQR | Complete | ||||
| Chronic Neutrophilic Leukemia (CNL) | Disease | Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera | FQR | PENDING | ||||
| Polycythaemia Vera (PV) | Disease | Gokce A. Toruner | FQR | PENDING | ||||
| Primary Myelofibrosis (PMF) | Disease | T. Niroshi Senaratne | FQR | PENDING | ||||
| Essential Thrombocythaemia (ET) | Disease | Rebecca Smith (trainee) + faculty TBD | FQR | PENDING | ||||
| Chronic Eosinophilic Leukemia, Not Otherwise Specified | Disease | Mark Evans (trainee), Fabiola Quintero-Rivera | FQR | PENDING | ||||
| Myeloproliferative Neoplasm (MPN), Unclassifiable | Disease | Mark Evans (trainee)+ Fabiola Quintero-Rivera | FQR | PENDING | ||||
| Mastocytosis | Overview | FQR | ||||||
| Cutaneous Mastocytosis | Disease | Thuy Phung | FQR | PENDING | ||||
| Systemic Mastocytosis | Disease | Shashi Shetty | FQR | PENDING | ||||
| Mast Cell Sarcoma | Disease | Thuy Phung | FQR | PENDING | ||||
| Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 | Overview | Daynna J.Wolff | FQR | PENDING | ||||
| Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement | Disease | Jay Alden (trainee) +Daynna J.Wolff | FQR | Complete | ||||
| Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement | Disease | Christopher Sullivan (trainee) + Daynna J.Wolff | FQR | Complete | ||||
| Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement | Disease | Yanna Ding | FQR | Complete | ||||
| Myeloid/Lymphoid Neoplasms with PCM1-JAK2 | Disease | Jessica Snider (trainee) + Daynna J.Wolff | FQR | Complete | ||||
| Myeloid/Lymphoid Neoplasms with ETV6-JAK2 | Disease | Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff | FQR | Complete | NON-WHO ENTITY | |||
| Myeloid/Lymphoid Neoplasms with BCR-JAK2 | Disease | Lauren R. Crowson (trainee) + Daynna J. Wolff | FQR | Complete | NON-WHO ENTITY | |||
| Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) | Overview | Linsheng Zhang | FQR | Complete | ||||
| Chronic Myelomonocytic Leukemia (CMML) | Disease | Linsheng Zhang | FQR | Complete | ||||
| Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | Disease | Linsheng Zhang | FQR | Complete | ||||
| Juvenile Myelomonocytic Leukemia (JMML) | Disease | Sarah Rapisardo | FQR | PENDING | ||||
| Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | Disease | Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera | FQR | PENDING | ||||
| Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | Disease | Ruth MacKinnon | FQR | PENDING | ||||
| Myelodysplastic Syndromes (MDS) | Overview | Teresa Smolarek? | FQR | |||||
| Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia | Disease | Xiaoli Du(trainee) +Teresa Smolarek | FQR | PENDING | ||||
| Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) | Disease | Xiaolin Hu(trainee)+Teresa Smolarek | FQR | Complete | ||||
| Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia | Disease | Xiaolin Hu(trainee)+Teresa Smolarek | FQR | Complete | ||||
| Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia | Disease | Xiaoli Du(trainee)+Teresa Smolarek | FQR | PENDING | ||||
| Myelodysplastic Syndrome (MDS) with Excess Blasts | Disease | Xiaoli Du(trainee)+Teresa Smolarek | FQR | PENDING | ||||
| Myelodysplastic Syndrome (MDS) with Isolated del(5q) | Disease | Xiaolin Hu(trainee)+Teresa Smolarek | FQR | Complete | ||||
| Myelodysplastic Syndrome (MDS), Unclassifiable | Disease | Xiaolin Hu(trainee)+Teresa Smolarek | FQR | PENDING | ||||
| Refractory Cytopenia of Childhood | Disease | Xiaoli Du(trainee)+Teresa Smolarek | FQR | PENDING | ||||
| Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms | Overview | Daynna Wolff+Daniel Butler (Path Resident) | Jennelle Hodge (JH)/ Malini Sathanoori (MS) | Complete | ||||
| Myeloid Neoplasms with Germline Predisposition | Overview | Ying Zou | JH / MS | Complete | ||||
| Acute Myeloid Leukaemia with Germline CEBPA Mutation | Disease | Daynna Wolff+Matthew Kilpatrick (Path Resident) | JH / MS | PENDING | ||||
| Myeloid Neoplasms with Germline DDX41 Mutation | Disease | Fei Yang | JH / MS | PENDING | ||||
| Myeloid Neoplasms with Germline RUNX1 Mutation | Disease | Malini Sathanoori | JH / MS | PENDING | ||||
| Myeloid Neoplasms with Germline ANKRD26 Mutation | Disease | Fei Yang | JH / MS | PENDING | ||||
| Myeloid Neoplasms with Germline ETV6 Mutation | Disease | Ying Zou | JH / MS | Complete | ||||
| Myeloid Neoplasms with Germline GATA2 Mutation | Disease | Daynna Wolff+ Alexandria Avery (Path Resident) | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities | Overview | Daynna Wolff+ Dan Wang (trainee) | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | Disease | Christine Bryke | JH / MS | Complete | ||||
| Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Disease | Christine Bryke | JH / MS | Complete | ||||
| Acute Promyelocytic Leukemia (APL) with PML-RARA | Disease | Shashi Shetty | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 | Disease | Shashi Shetty | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 | Disease | Jennelle Hodge | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM | Disease | Gordana Raca | JH / MS | Complete | Need permission for figure? Update WHO? | |||
| Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 | Disease | Jennelle Hodge | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with BCR-ABL1 | Disease | Kay Weng Choy + Greg Conboy (Monash Health) | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with Mutated NPM1 | Disease | Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health) | JH / MS | Complete | Add WHO reference | |||
| Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA | Disease | Paul deFazio, MSc + Greg Conboy (Monash Health) | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with Mutated RUNX1 | Disease | Daynna Wolff+Iris Martin (Path Resident) | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | Disease | Fei Yang | JH / MS | Complete | ||||
| Therapy-Related Myeloid Neoplasms | Disease | Shashi Shetty + Shawn A. Silver (resident) | JH / MS | Complete | Check reference format | |||
| Acute Myeloid Leukemia (AML), Not Otherwise Specified | Overview | Anwar Iqbal | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with Minimal Differentiation | Disease | Fabiola Quintero-Rivera and Celeste Eno (fellow) | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) without Maturation | Disease | Jennelle Hodge | JH / MS | Complete | ||||
| Acute Myeloid Leukemia (AML) with Maturation | Disease | Jennelle Hodge | JH / MS | Complete | ||||
| Acute Myelomonocytic Leukemia | Disease | Fei Yang | JH / MS | Complete | ||||
| Acute Monoblastic and Monocytic Leukemia | Disease | Fei Yang | JH / MS | Complete | ||||
| Pure Erythroid Leukemia | Disease | Ash Yenamandra | JH / MS | Complete | ||||
| Acute Megakaryoblastic Leukemia (AMKL) | Disease | Fei Yang | JH / MS | Complete | ||||
| Acute Basophilic Leukemia | Disease | Ash Yenamandra | JH / MS | Complete | ||||
| Acute Panmyelosis with Myelofibrosis | Disease | Ying Zou and Jialing Huang (MGP fellow) | JH / MS | Complete | ||||
| Myeloid Sarcoma | Disease | Fabiola Quintero-Rivera | JH / MS | Complete | ||||
| Myeloid Proliferations Associated with Down Syndrome | Overview | Patty Greipp | JH / MS | Complete | Need permission for figure? | |||
| Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome | Disease | Linda Cooley | JH / MS | Complete | ||||
| Myeloid Leukemia Associated with Down Syndrome | Disease | Linda Cooley | JH / MS | Complete | ||||
| Blastic Plasmacytoid Dendritic Cell Neoplasm | Disease | Daynna Wolff+Hao Liu (Path Resident) | JH / MS | Complete | ||||
| Acute Leukemias of Ambiguous Lineage | Overview | Hui Chen/ Jennelle Hodge | JH / MS | Complete | ||||
| Acute Undifferentiated Leukemia | Disease | Shashi Shetty + Amelia Nakanishi (resident) | JH / MS | Complete | Check reference format | |||
| Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 | Disease | Tracy Tucker | JH / MS | Complete | ||||
| Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged | Disease | Tracy Tucker | JH / MS | Complete | ||||
| Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified | Disease | Shashi Shetty + Priyatharsini Nirmalanantham (resident) | JH / MS | Complete | Check reference format | |||
| Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | Disease | Fabiola Quintero-Rivera | JH / MS | Complete | ||||
| ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types | Disease | JH / MS | ?? | |||||
| ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS) | Disease | JH / MS | ?? | |||||
| Acute Myeloid Leukemia (AML) with Mutated FLT3 | Disease | Kay Weng Choy + Greg Conboy (Monash Health) | JH / MS | Complete | NON-WHO ENTITY | |||
| Acute Myeloid Leukemia (AML) with NUP214-ABL1 | Disease | Daynna Wolff+Jessica Snider (Path Resident) | JH / MS | PENDING | NON-WHO ENTITY | |||
| Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6 | Disease | Daynna Wolff+ Paige Woodham (Path Resident) | JH / MS | PENDING | NON-WHO ENTITY | |||
| Precursor Lymphoid Neoplasms | Overview | Yassmine Akkari (YA) | ||||||
| B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities | Overview | YA | ||||||
| B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | Disease | YA | ||||||
| B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged | Disease | Yassmine Akkari+Nicolas Millan (trainee) | YA | PENDING | ||||
| B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 | Disease | YA | ||||||
| B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | Disease | YA | ||||||
| B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | Disease | Ashwini Yenamandra +
Lisa Smith + Yassmine Akkari |
YA | Complete | ||||
| B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 | Disease | YA | ||||||
| B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 | Disease | YA | ||||||
| B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Disease | Mark G. Evans + Fabiola Quintero-Rivera | YA | Complete | ||||
| B-Lymphoblastic Leukemia/Lymphoma with iAMP21 | Disease | YA | ||||||
| B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified | Disease | YA | ||||||
| T-Lymphoblastic Leukemia/Lymphoma | Overview | YA | ||||||
| Early T-Cell Precursor Lymphoblastic Leukemia | Disease | YA | ||||||
| NK-Lymphoblastic Leukemia/Lymphoma | Disease | YA | ||||||
| B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements | Disease | Helene Bruyere | YA | PENDING | NON-WHO ENTITY | |||
| Mature B-Cell Neoplasms | Overview | Snehal Patel (SP) | ||||||
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Disease | Honey Reddi | SP | PENDING | ||||
| Monoclonal B-cell Lymphocytosis | Disease | Honey Reddi | SP | PENDING | ||||
| B-cell Prolymphocytic Leukemia | Disease | Honey Reddi | SP | PENDING | ||||
| Splenic Marginal Zone Lymphoma | Disease | Snehal Patel | SP | Complete | Malini to review | |||
| Hairy Cell Leukemia | Disease | Snehal Patel | SP | Complete | Malini to review | |||
| Splenic B-cell Lymphoma/Leukemia, Unclassifiable | Overview | Snehal Patel | SP | Complete | Malini to review | |||
| Splenic Diffuse Red Pulp Small B-cell Lymphoma | Disease | Snehal Patel | SP | Complete | Malini to review | |||
| Hairy Cell Leukemia Variant | Disease | Snehal Patel | SP | Complete | Malini to review | |||
| Lymphoplasmacytic Lymphoma | Disease | Honey Reddi | SP | PENDING | ||||
| Waldenstrom Macroglobulinemia | Disease | Honey Reddi | SP | PENDING | ||||
| IgM Monoclonal Gammopathy of Undetermined Significance | Disease | SP | ||||||
| Heavy Chain Diseases | Overview | SP | ||||||
| Mu Heavy Chain Disease | Disease | SP | ||||||
| Gamma Heavy Chain Disease | Disease | SP | ||||||
| Alpha Heavy Chain Disease | Disease | SP | ||||||
| Plasma Cell Neoplasms | Overview | Zhenya Tang | SP | PENDING | ||||
| Non-IgM Monoclonal Gammopathy of Undetermined Significance | Disease | Zhenya Tang | SP | PENDING | ||||
| Plasma Cell Myeloma | Disease | Zhenya Tang/Huang Mo (trainee) | SP | PENDING | ||||
| Plasma Cell Myeloma Variants | Disease | Zhenya Tang | SP | PENDING | ||||
| Plasmacytoma | Disease | Zhenya Tang | SP | PENDING | ||||
| Monoclonal Immunoglobulin Deposition Diseases | Overview | SP | ||||||
| Primary Amyloidosis | Disease | SP | ||||||
| Light Chain and Heavy Chain Deposition Disease | Disease | SP | ||||||
| Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome | Overview | SP | ||||||
| POEMS Syndrome | Disease | SP | ||||||
| TEMPI Syndrome | Disease | SP | ||||||
| Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | Disease | Zhenya Tang & Trainee | SP | PENDING | ||||
| Nodal Marginal Zone Lymphoma | Disease | SP | ||||||
| Paediatric Nodal Marginal Zone Lymphoma | Disease | Ruthann Pfau, Kathleen Schieffer (trainee) | SP | PENDING | ||||
| Follicular Lymphoma | Disease | Ruthann Pfau | SP | PENDING | ||||
| Testicular Follicular Lymphoma | Disease | Ruthann Pfau | SP | PENDING | ||||
| In Situ Follicular Neoplasia | Disease | Ruthann Pfau | SP | PENDING | ||||
| Duodenal-Type Follicular Lymphoma | Disease | Ruthann Pfau | SP | PENDING | ||||
| Paediatric-Type Follicular Lymphoma | Disease | Ruthann Pfau, Kathleen Schieffer (trainee) | SP | PENDING | ||||
| Large B-cell Lymphoma with IRF4 Rearrangement | Disease | SP | ||||||
| Primary Cutaneous Follicle Centre Lymphoma | Disease | SP | ||||||
| Mantle Cell Lymphoma | Disease | Mahsa Khanlari | SP | PENDING - due 8/15/20 | ||||
| Leukemic Non-Nodal Mantle Cell Lymphoma | Disease | Mahsa Khanlari | SP | PENDING - due 8/31/20 | ||||
| In Situ Mantle Cell Neoplasia | Disease | Mahsa Khanlari | SP | PENDING - due 8/15/20 | ||||
| Diffuse Large B-cell Lymphoma, Not Otherwise Specified | Disease | Ashwini Yenamandra | Greg Corboy (GC) | PENDING | ||||
| T-cell/Histiocyte-Rich Large B-cell Lymphoma | Disease | GC | ||||||
| Primary Diffuse Large B-cell Lymphoma of the CNS | Disease | GC | ||||||
| Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type | Disease | GC | ||||||
| EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS) | Disease | GC | ||||||
| EBV-Positive Mucocutaneous Ulcer | Disease | GC | ||||||
| Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation | Disease | GC | ||||||
| Fibrin-Associated Diffuse Large B-cell Lymphoma | Disease | GC | ||||||
| Lymphomatoid Granulomatosis | Disease | GC | ||||||
| Primary Mediastinal (Thymic) Large B-cell Lymphoma | Disease | GC | ||||||
| Intravascular Large B-cell Lymphoma | Disease | GC | ||||||
| ALK-Positive Large B-cell Lymphoma | Disease | GC | ||||||
| Plasmablastic Lymphoma | Disease | Mark Evans (trainee), Fabiola Quintero-Rivera | GC | Complete | ||||
| Primary Effusion Lymphoma | Disease | GC | ||||||
| HHV8-Associated Lymphoproliferative Disorders | Overview | GC | ||||||
| Multicentric Castleman Disease | Disease | GC | ||||||
| HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS) | Disease | GC | ||||||
| HHV8-Positive Germinotropic Lymphoproliferative Disorder | Disease | GC | ||||||
| Burkitt Lymphoma | Disease | GC | ||||||
| Burkitt-Like Lymphoma with 11q Aberration | Disease | GC | ||||||
| High-Grade B-cell Lymphoma | Overview | GC | ||||||
| High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | Disease | GC | ||||||
| High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | Disease | GC | ||||||
| B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma | Disease | GC | ||||||
| Mature T- and NK-cell Neoplasms | Overview | Snehal Patel (SP) | ||||||
| T-cell Prolymphocytic Leukemia | Disease | Michelle Don | SP | PENDING | ||||
| T-cell Large Granular Lymphocytic Leukemia | Disease | Michelle Don | SP | PENDING | ||||
| Chronic Lymphoproliferative Disorder of NK Cells | Disease | Michelle Don | SP | PENDING | ||||
| Aggressive NK-cell Leukemia | Disease | SP | ||||||
| EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood | Overview | SP | ||||||
| Systemic EBV-Positive T-cell Lymphoma of Childhood | Disease | SP | ||||||
| Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form | Disease | SP | ||||||
| Hydroa Vacciniforme-Like Lymphoproliferative Disorder | Disease | SP | ||||||
| Severe Mosquito Bite Allergy | Disease | SP | ||||||
| Adult T-cell Leukemia/Lymphoma | Disease | SP | ||||||
| Extranodal NK/T-cell Lymphoma, Nasal Type | Disease | SP | ||||||
| Intestinal T-cell Lymphoma | Overview | Sumire Kitahara, Derick Okwan (trainee) | SP | PENDING | ||||
| Enteropathy-Associated T-cell Lymphoma | Disease | Sumire Kitahara, Derick Okwan (trainee) | SP | PENDING | ||||
| Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | Disease | Sumire Kitahara | SP | PENDING | ||||
| Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | Disease | Sumire Kitahara, Derick Okwan (trainee) | SP | PENDING | ||||
| Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | Disease | Sumire Kitahara, Derick Okwan (trainee) | SP | PENDING | ||||
| Hepatosplenic T-cell Lymphoma | Disease | Michelle Don | SP | PENDING | ||||
| Subcutaneous Panniculitis-Like T-cell Lymphoma | Disease | SP | ||||||
| Mycosis Fungoides | Disease | SP | ||||||
| Sézary Syndrome | Disease | SP | ||||||
| Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders | Overview | SP | ||||||
| Lymphomatoid Papulosis | Disease | SP | ||||||
| Primary Cutaneous Anaplastic Large Cell Lymphoma | Disease | SP | ||||||
| Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes | Overview | SP | ||||||
| Primary Cutaneous Gamma Delta T-cell Lymphoma | Disease | SP | ||||||
| Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma | Disease | SP | ||||||
| Primary Cutaneous Acral CD8+ T-cell Lymphoma | Disease | SP | ||||||
| Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder | Disease | SP | ||||||
| Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS) | Disease | SP | ||||||
| Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin | Overview | SP | ||||||
| Angioimmunoblastic T-cell Lymphoma | Disease | Ruthann Pfau, Sara Akhavanfard (trainee) | SP | PENDING | ||||
| Follicular T-cell Lymphoma | Disease | Ruthann Pfau, Sara Akhavanfard (trainee) | SP | PENDING | ||||
| Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | Disease | SP | ||||||
| Anaplastic Large Cell Lymphoma, ALK-Positive | Disease | Sumire Kitahara | SP | PENDING | ||||
| Anaplastic Large Cell Lymphoma, ALK-Negative | Disease | Sumire Kitahara | SP | PENDING | ||||
| Breast Implant-Associated Anaplastic Large Cell Lymphoma | Disease | Sumire Kitahara | SP | PENDING | ||||
| Hodgkin Lymphomas | Overview | Associate Editor?? | ||||||
| Nodular Lymphocyte Predominant Hodgkin Lymphoma | Disease | |||||||
| Classic Hodgkin Lymphoma | Overview | |||||||
| Nodular Sclerosis Classic Hodgkin Lymphoma | Disease | |||||||
| Lymphocyte-Rich Classic Hodgkin Lymphoma | Disease | |||||||
| Mixed Cellularity Classic Hodgkin Lymphoma | Disease | |||||||
| Lymphocyte-Depleted Classic Hodgkin Lymphoma | Disease | |||||||
| Immunodeficiency-Associated Lymphoproliferative Disorders | Overview | |||||||
| Lymphomas Associated with HIV Infection | Disease | |||||||
| Post-Transplant Lymphoproliferative Disorders | Overview | |||||||
| Non-Destructive Post-Transplant Lymphoproliferative Disorders | Disease | |||||||
| Polymorphic Post-Transplant Lymphoproliferative Disorders | Disease | Anna Shestakova (trainee)+,
Fabiola Quintero-Rivera |
PENDING | |||||
| Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types) | Overview | |||||||
| Monomorphic B-cell PTLD | Disease | |||||||
| Monomorphic T/NK-cell PTLD | Disease | |||||||
| Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder | Disease | |||||||
| Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders | Disease | |||||||
| Histiocytic and Dendritic Cell Neoplasms | Overview | |||||||
| Histiocytic Sarcoma | Disease | |||||||
| Tumors Derived From Langerhans Cells | Overview | |||||||
| Langerhans Cell Histiocytosis | Disease | |||||||
| Langerhans Cell Sarcoma | Disease | |||||||
| Indeterminate Dendritic Cell Tumour | Disease | |||||||
| Interdigitating Dendritic Cell Sarcoma | Disease | |||||||
| Follicular Dendritic Cell Sarcoma | Disease | |||||||
| Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma | Disease | |||||||
| Fibroblastic Reticular Cell Tumor | Disease | |||||||
| Disseminated Juvenile Xanthogranuloma | Disease | |||||||
| Erdheim-Chester Disease | Disease | |||||||
| Gene | Author | Associate Editor | Author Content
(Pending or Complete) |
Editor Reviewed (Date) | Notes |
|---|---|---|---|---|---|
| BCR | Brian Davis | Complete (8/10/18) | |||
| ABL1 | Brian Davis | Complete (4/16/19) | |||
| RUNX1 | Brian Davis | Complete (6/9/19) | |||
| RUNX1T1 | Brian Davis | Complete (5/23/19) | |||
| MYH11 | Brian Davis | Complete (8/6/18) | |||
| FLT3 | Kay Weng Choy | Complete ( | |||
| NPM1 | Kay Weng Choy | Complete ( | |||
| TP53 | Kay Weng Choy | Complete ( | |||
| DNMT3A | Kay Weng Choy | Complete ( | |||
| CEBPA | Gordana | Complete ( | |||
| IDH1 | Paul De Fazio | Complete ( | |||
| IDH2 | Paul De Fazio | Complete ( | |||
| PML | Brian Davis | Complete (12/5/18) | |||
| RARA | Brian Davis | Complete (8/3/18) | |||
| ETV6 | Brian Davis | Complete (6/9/19) | |||
| KIT | Brian Davis | Complete (10/1/18) | |||
| CBFB | Brian Davis | Complete (8/2/18) | |||
| GATA2 | Kay Weng Choy | Complete ( | |||
| PTEN | Beth Pitel | Pending | |||
| MLTT3 | |||||
| MECOM | Brian Davis | Pending | |||
| FGFR1(FLT2) | Brian Davis | Pending | |||
| KMT2A | |||||
| DEK | |||||
| NUP214 | |||||
| RBM15 | |||||
| MKL1 | |||||
| DDX41 | |||||
| ANKRD26 | |||||
| CUX1 | |||||
| TET2 | |||||
| EZH2 | |||||
| FOXP1 | |||||
| MYC | |||||
| JAK2 | |||||
| WT1 | |||||
| CBL | |||||
| NF1 | |||||
| SUZ12 | |||||
| ERG | |||||
| EST2 | |||||
| RPS14 | |||||
| RB1 | |||||
| MPL | |||||
| CHGA | |||||
| CDH1 | |||||
| SRSF2 | |||||
| DNMT1 | |||||
| PRDX2 | |||||
| ASXL1 | |||||
| MN1 | |||||
| SF3A1 | |||||
| EP300 | |||||
| JARID2 | |||||